Getting Started With Jakafi in cGVHD

START: Initiate therapy with the appropriate dose1

START: Initiate therapy with the appropriate dose1
- Jakafi is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older
- Evaluate blood parameters before and during treatment with Jakafi



MONITOR: Monitoring patients after initiation of Jakafi is essential1

MONITOR: Monitoring patients after initiation of Jakafi is essential1
Dose reductions should be considered for platelet counts, ANCs, or bilirubin elevation as described below (see Jakafi Dose Modifications) and in the Full Prescribing Information.

OPTIMIZE: Individualize dosing of Jakafi to optimize the balance between safety and efficacy1

OPTIMIZE: Individualize dosing of Jakafi to optimize the balance between safety and efficacy1
Doses may be modified based on safety and efficacy.
- Dose reductions may be used to manage side effects:
- 10 mg twice daily may be reduced to 5 mg twice daily
- 5 mg twice daily may be reduced to 5 mg once daily
- Patients who are unable to tolerate Jakafi at 5 mg once daily should have treatment interrupted until their clinical and/or laboratory parameters recover
- Tapering may be considered after 6 months of treatment in patients with response who have discontinued therapeutic doses of corticosteroids
- Taper Jakafi by 1 dose level approximately every 8 weeks (10 mg BID to 5 mg BID to 5 mg QD)
- If GVHD signs or symptoms recur during or after the taper of Jakafi, consider retreatment
Reference:
- Jakafi Prescribing Information. Wilmington, DE: Incyte Corporation
Jakafi Dose Modifications
View the dosing modifications for patients with cytopenias, elevated total bilirubin, hepatic or renal impairment, and when used with strong CYP3A4 inhibitors or fluconazole.
ANC, absolute neutrophil count; CYP3A4, Cytochrome P450 3A4.